Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
(2011) Breast cancer research : BCR — Vol. 13, n° 1, p. R17 (2011)
Files
document.pdf
Open Access - Adobe PDF
- 842.88 KB
Details
- Authors
- Abstract
- Anti-trastuzumab anti-Id scFv69, used as a therapeutic or prophylactic vaccine, protects mice from developing HER2-positive mammary tumors by inducing both anti-HER2 Ab1' antibody production and an anti-HER2 Th2-dependent immune response. These results suggest that scFv69 could be used as an anti-Id-based vaccine for adjuvant therapy of patients with HER2-positive tumors to reverse immunological tolerance to HER2.
Citations
Ladjemi, M. Z., Chardes, T., Corgnac, S., Garambois, V., Morisseau, S., Robert, B., Bascoul-Mollevi, C., Ait Arsa, I., Jacot, W., Pouget, J.-P., Pelegrin, A., & Navarro-Teulon, I. (2011). Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast cancer research : BCR, 13(1), R17. https://doi.org/10.1186/bcr2826 (Original work published 2011)